Prescription drug · NDA
Baqsimi (glucagon) NDC 85766-212
Glucagon 3 mg/1 · Powder · Nasal · Sportpharm LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 85766-212-03 | 85766021203 | 1 TUBE in 1 CARTON (85766-212-03) / 1 BOTTLE, UNIT-DOSE in 1 TUBE / 1 POWDER in 1 BOTTLE, UNIT-DOSEMarketed from Jun 19, 2026 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Baqsimi
- Generic name (nonproprietary)
- glucagon
- Active ingredients
- Glucagon — 3 mg/1
- Dosage form
- Powder
- Route
- Nasal
- Labeler
- Sportpharm LLC
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 210134
- Marketing start
- Listing expires
- Other FDA classes
- Decreased GI Motility (Physiologic effect)Decreased GI Smooth Muscle Tone (Physiologic effect)Decreased Glycolysis (Physiologic effect)Increased Gluconeogenesis (Physiologic effect)Increased Glycogenolysis (Physiologic effect)
- Identifiers
- Product ID 85766-212_54988ebe-c60f-a434-e063-6394a90a20d5SPL ID 54988ebe-c60f-a434-e063-6394a90a20d5SPL set ID 32ba41fa-4158-40af-8cb2-03693c248994RxCUI 2180666, 2180671UNII 76LA80IG2G
- Pharmacologic class
- Antihypoglycemic Agent; Gastrointestinal Motility Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Nasal products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N485766021203followed by a unit qualifier and the quantityPackage 85766-0212-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
BAQSIMI™ is indicated for the treatment of severe hypoglycemia in adults and pediatric patients aged 1 year and older with diabetes. BAQSIMI ® is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in adults and pediatric patients aged 1 year and older with diabetes. ( 1 )
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 210134
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.